Comparison of different brands of centrally acting skeletal muscle relaxants: a cost analysis study

Kiran B., Kala P., Chitra N. S., Jamuna Rani R.


Background: Skeletal muscle relaxants are structurally distinct drugs prescribed for reducing muscle spasms, pain, and hyperreflexia. Centrally acting skeletal muscle relaxants are manufactured by various pharmaceutical companies with variable price. The present study, aimed to analyze the cost variation of various brands of centrally acting skeletal muscle relaxants, so as to help the physician to choose the cost effective treatment.

Methods: Current index of medical stores (CIMS) April 2018 and online literature were used as information guide to review the prices of drugs used in the treatment of musculo skeletal pain and spastic neurological disorders.

Results: Among anti spasmodic group, thiocolchicoside 4 mg shows maximum price variation of 337.5%, whereas carisoprodol 350 mg shows the least variation of 0.1%. It is evident from antispastic group that baclofen 10 mg shows maximum price variation of 93.91% and 5 mg of Baclofen shows the least variation of 11.22%. It is observed that, among anti spastic group, a percentage prize variation of 93.91 for 10 mg and 11.22 for 5 mg baclofen. Largest % prize variation is seen in metaxalone + diclofenac sodium (400+50) mg as 525% and the least variation is observed in tolperisone+ paracetamol (150+325) mg as 3.88%.

Conclusions: Centrally acting orally effective skeletal muscle relaxants are commonly prescribed for painful musculoskeletal and spastic neurological disorders. Physicians should give due importance for the cost of the drugs while selecting appropriate drug for musculo skeletal disorders.


Anti spasmolytic, Anti spasmodic, Cost analysis, Skeletal muscle relaxants

Full Text:



Van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for nonspecific low back pain: A systematic review within the framework of the Cochrane Collaboration. Spine. 2003;28:1978-92.

Definition of Muscle relaxant. Available at: (c) 1996-2007. (Accessed on 21 May 2019).

Muscle relaxant. Available at: mediLexicon. (c) 2007. (Accessed 20 May 2019).

Witenko C, Moorman-Li R, Motycka C, Duane K, Hincapie-Castillo J, Leonard P, et al. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. Pharma Therapeutics. 2014;39(6):427.

Chou R, Qaseem A, Snow V, Casey D, Cross JT, Shekelle P, Owens DK. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Internal Med. 2007;147(7):478-91.

See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008;28(2):207-13.

See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008;78(3):365-70.

Atlas SJ, Deyo RA. Evaluating and managing acute low back pain in the acute care setting. J Gen Intern Med. 2001;16(2):120-31.

Van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the cochrane collaboration. Spine. 2003;28(17):1978-92.

Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxolone. Clin Ther. 2004;26(9):1355-67.

Garnett WR. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy: J Hum Pharmacol Drug Therapy. 2000;20(8P2):191S-9S.

Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS, et al. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015;52:14-8.